CAS: 91523-05-6; (6S,8S,9S,10R,13S,14S,17R)-17-Hydroxy-17-(2-Hydroxyacetyl)-6,10,13-Trimethyl-7,8,9,10,12,13,14,15,16,17-Decahydro-3H-Cyclopenta[a]Phenanthrene-3,11(6H)-Dione (Fluocortolone Impurity)

相似化合物

115321-98-7 2036-77-3 2601-23-2

上下游产品

Methylprednisolone c-dien-3-one11β,21-dihydroxy-6α-methyl-pregna-4,17(20)c-dien-3-one c-trien-3-one21-acetoxy-11β-hydroxy-6α-methyl-pregna-1,4,17(20)c-trien-3-one methylprednisolone acetate

专利信息

专利号:US-9994558-B2
优先权日:2013-09-20
标题 :Multicyclic compounds and methods of using same
发明人：BALOGLU ERKAN; SHACHAM SHARON; SENAPEDIS WILLIAM; MCCAULEY DILARA; LANDESMAN YOSEF; GOLAN GALI; KALID ORI; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).

专利号:EP-4341253-A1
优先权日:2021-05-20
标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms

专利号:US-2017369470-A1
优先权日:2014-12-16
标 题:Cyclic Compounds and Uses Thereof
发明人：BALOGLU ERKAN; SENAPEDIS WILLIAM; SHACHAM SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted benzothiophenyl, substituted benzothiazolyl, substituted indolyl and substituted benzoimidazolyl compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, inflammatory diseases or an autoimmune system disease (e.g., a T-Cell mediated autoimmune disesase).

专利号:US-2019002448-A1
优先权日:2015-12-31
标 题 :Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
发明人：BALOGLU ERKAN
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (I) or (II), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula A, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

专利号:US-9938258-B2
优先权日:2012-11-29
标 题:Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
发明人：BALOGLU ERKAN; SHECHTER SHARON; SHACHAM SHARON; MCCAULEY DILARA; SENAPEDIS WILLIAM; GOLAN GALI; KALID ORI
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: n nor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.

专利号:US-2016016916-A1
优先权日:2013-03-15
标 题:Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
发明人：SANDANAYAKA VINCENT P; SHECHTER SHARON; DAELEMANS DIRK; LEEN VOLKER; DEHAEN WIM ALFRONS; SHACHAM SHARON
权利人:KARYOPHARM THERAPEUTICS INC; KATOLIEKE UNIVERSITEIT LEUVEN
摘要:The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and, more particularly, to a compound represented by structural formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.